Logo

Adnavance Raises $3.7M in Series B Financing

Feb 26, 2008
NEW YORK (GenomeWeb News) – Molecular diagnostics developer Adnavance Technologies said today it has taken in CDN$3.7 million (US$3.7 million) in a Series B financing.
 
The funding round was headed by Working Opportunity Fund, which is managed by GrowthWorks Capital, JovInvestment Management, and Business Development Bank of Canada.
 
Adnavance, which has its headquarters in Vancouver, British Columbia, and a lab in Saskatoon, Saskatchewan, plans to use the funds to continue to develop and expand its metalized-DNA technology, which the company said “may eliminate the need for target amplification for a large number of molecular diagnostic tests.”
 
Adnavance also said it has named former Nanogen and Xenomics CEO Randy White to be CEO of the company.

Breaking News
The Scan

Myotonic Dystrophy Repeat Detected in Family Genome Sequencing Analysis

While sequencing individuals from a multi-generation family, researchers identified a myotonic dystrophy type 2-related short tandem repeat in the European Journal of Human Genetics.

TB Resistance Insights Gleaned From Genome Sequence, Antimicrobial Response Assays

Researchers in PLOS Biology explore M. tuberculosis resistance with a combination of sequencing and assays looking at the minimum inhibitory concentrations of 13 drugs.

Mendelian Disease Genes Prioritized Using Tissue-Specific Expression Clues

Mendelian gene candidates could be flagged for further functional analyses based on tissue-specific transcriptome and proteome profiles, a new Journal of Human Genetics paper says.

Single-Cell Sequencing Points to Embryo Mosaicism

Mosaicism may affect preimplantation genetic tests for aneuploidy, a single-cell sequencing-based analysis of almost three dozen embryos in PLOS Genetics finds.